Stock analysts at Stifel Nicolaus initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) in a report issued on Friday, Briefing.com reports. The firm set a “buy” rating and a $49.00 price target on the stock. Stifel Nicolaus’ price target points to a potential upside of 88.46% from the company’s previous close.
A number of other research firms have also recently issued reports on ORKA. Leerink Partners assumed coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective for the company. TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Lifesci Capital assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price target for the company. Finally, HC Wainwright initiated coverage on Oruka Therapeutics in a research note on Monday. They set a “buy” rating and a $45.00 price target for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $43.17.
Get Our Latest Research Report on Oruka Therapeutics
Oruka Therapeutics Trading Down 8.6 %
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Oruka Therapeutics will post -1.62 EPS for the current year.
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- 3 Monster Growth Stocks to Buy Now
- S&P 500 Hits Record Highs: 3 Stocks With Huge Growth Potential
- What is the S&P 500 and How It is Distinct from Other Indexes
- AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
- What Does a Stock Split Mean?
- AZZ Stock Gains Momentum: Analysts Forecast 25% Upside From Here
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.